Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts XENE Hot Sheet
Join SI Premium – FREE
Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.75), $0.05 worse than the analyst estimate of ($0.70).
For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blue Owl leads $2.4 billion debt deal for Iren data center
- Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
- Hafnia Limited (HAFN) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
